Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil for HFpEF with combined pre- and post-capillary pulmonary hypertension
ChiCTR2100041875Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tadalafil in heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Peak oxygen uptake. Started Jan 2021; status: recruiting.
02
Drugs
tadalafil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on ChiCTR2100041875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041875.